Clinical UM Guideline

This document addresses the use of home phototherapy and the devices used for the treatment of neonatal jaundice that is physiologic (that is, non-pathologic) in nature. In utero, the fetus requires larger amounts of hemoglobin for oxygenation. After birth, the need is reduced and hemoglobin is rapidly destroyed, producing increased levels of bilirubin. Jaundice results when the neonate’s liver is unable to efficiently clear the accumulating bilirubin. Neonatal jaundice is a common occurrence and is frequently treated in the home setting. Infants with very high levels of bilirubin may be managed in the inpatient setting.

Medically Necessary:

Home phototherapy devices are considered medically necessary when the criteria below are met:

1. The infant has neonatal hyperbilirubinemia; and
2. Is ready to be discharged from the hospital or is already discharged; and
3. Has no known hyperbilirubinemia neurotoxicity risk factors; and
4. Total serum bilirubin concentration is no more than 1 mg/dL above the phototherapy treatment threshold as defined by the American Academy of Pediatrics Clinical Practice Guideline*; and
5. Phototherapy equipment used in the home, such as a fiberoptic blanket or band, is provided by a durable medical equipment (DME) provider.

*American Academy of Pediatrics Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation is available at: https://publications.aap.org/pediatrics/article/150/3/e2022058859/188726/Clinical-Practice-Guideline-Revision-Management-of?searchresult=1)

Not Medically Necessary:

Home phototherapy devices for neonatal hyperbilirubinemia are considered not medically necessary when the criteria above have not been met.

Home phototherapy devices for neonatal hyperbilirubinemia are considered not medically necessary when more than one phototherapy device (intensive phototherapy) is used in the home setting.

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure codes listed above when criteria are not met or for situations designated in the Clinical Indications section as not medically necessary.

Hyperbilirubinemia is the most common condition requiring medical attention in newborns. A total of 50% of term neonates and 80% of preterm neonates develop jaundice in the first week of life. The jaundiced skin and sclera in newborns is the result of accumulation of unconjugated bilirubin. In most infants, unconjugated hyperbilirubinemia reflects a normal transitional phenomenon. However, in some infants, serum bilirubin levels may rise excessively, which can be a cause for concern as unconjugated bilirubin can be neurotoxic. As total serum bilirubin (TSB) rises closer to the phototherapy threshold, the potential need for escalation of care or future phototherapy also rises. The American Academy of Pediatrics (AAP) guideline for the Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation (Kemper, 2022) notes that some infants are at greater risk of developing bilirubin neurotoxicity. Those risk factors include gestational age less than 38 weeks; albumin less than 3.0 g/dL; isoimmune hemolytic disease (for instance, positive direct antiglobulin test), G6PD deficiency, or other hemolytic conditions; sepsis; and significant clinical instability in the previous 24 hours. Therefore, the presence of neonatal jaundice frequently requires diagnostic evaluation and treatment.

In the hospital setting, phototherapy is delivered by exposing the infant to fluorescent light. When this type of light source is used, the infant’s eyes are protected from the lights with a mask. The infant is positioned in an incubator wearing only a diaper, exposing as much of the infant’s skin surface as possible to the light source. For those infants with very high bilirubin levels, intensive phototherapy may be used. This type of phototherapy employs two light sources such as fluorescent and fiber optic light. The 2022 AAP guideline indicates, “Intensive phototherapy requires a narrow-spectrum LED blue light with an irradiance of at least 30 µW/cm² per nm at a wavelength around 475 nm.”

In the home setting, phototherapy is accomplished by using a blanket or a neck ring that emits fiber optic light. This light is directed below the infant’s head and is less intense than fluorescent light; therefore, masking the infant’s eyes is not necessary. The infant can also be fed without interrupting therapy. For home phototherapy to be safe and effective, the caregivers must be compliant with the treatment protocol and daily follow-up appointments must be kept. Additionally, the infant should be alert, eating, and voiding and stooling well. If the serum bilirubin level is rising in spite of home phototherapy, the infant may be treated with intensive phototherapy in the inpatient setting.

Regarding home phototherapy, the 2022 AAP guideline states:

Home phototherapy can be less costly and disruptive to family routines and breastfeeding and may help improve bonding and reduce stress compared with readmission for phototherapy. However, its effectiveness depends on the quality of the home phototherapy device as well as the ability of the family to appropriately use it. Therefore, caution is needed when considering home phototherapy. Furthermore, home phototherapy is not recommended for infants with any hyperbilirubinemia neurotoxicity risk factor.

Home phototherapy should not be used if there is any question about the quality of the home phototherapy device, the ability to have the device delivered to the home rapidly, concerns about the family’s ability to use the device, or concerns about the ability to measure bilirubin concentrations daily. As with inpatient phototherapy, it is an option to start home phototherapy at a lower threshold (eg, 2 mg/dL below the phototherapy threshold) to reduce the readmission risk.

The document also provides guidance on discontinuation of phototherapy. That guidance indicates:

Discontinuing phototherapy is an option when the TSB has decreased by at least 2 mg/dL below the hour-specific threshold at the initiation of phototherapy. A longer period of phototherapy is an option if there are risk factors for rebound hyperbilirubinemia (eg, gestational age <38 weeks, age <48 hours at the start of phototherapy, hemolytic disease).

The AAP/American College of Obstetrics and Gynecologists (ACOG) guidelines for perinatal care (2017) state that home phototherapy is a therapy option and eligible candidates require proper home care follow-up and supervision including obtaining blood samples to measure TSB levels. This is to allow for close monitoring to ensure TSB levels are decreasing, and to ensure swift intervention in the event that levels are not responding to home phototherapy.

In 2020, Chang and Waite published the results of a retrospective cohort study evaluating home phototherapy for neonatal hyperbilirubinemia. A total of 1324 infants born at ≥ 35 weeks gestation met inclusion criteria. The primary endpoint was hospitalization for inpatient phototherapy during or within 24 hours of completion of home phototherapy. The mean initial TSB was 16.9 ± 2.5 mg/dl, the mean duration of treatment was 53 hours (interquartile range [IQR], 44-72 hours; range, 15-280 hours), the median number of home nursing visits was 4 (IQR, 4-5; range, 3-13). All infants were treated with the BiliBed^® (Medela, McHenry, IL) and a total of 414 (31.3%) infants were treated with both the BiliBed and a fiberoptic pad. The mean rate of TSB decline was similar for infants that were treated using BiliBed only versus the BiliBed and fiberoptic pad (0.08 ± 0.06 mg/dL/hour versus 0.09 ± 0.07 mg/dL/hour; p=0.14). A total of 25 infants were admitted to the hospital, 15 were admitted for rising TSB levels and 3/15 caregivers were not compliant with home phototherapy due to “fussiness.” A total of 14/15 infants with rising TSB levels had TSB above the treatment threshold (mean 3.7 ± 2.6 mg/dL above). The remaining 10 admissions were a result of parental request (n=3), other clinical concern (n=6), and power outage (n=1); 5 of these admissions had TSB above the treatment threshold and 5 were below. A second course of treatment was required for 18 infants (1.4%; 95% confidence interval [CI], 0.9-2.1%). Starting home phototherapy at or above the AAP treatment threshold was a risk factor for admission or repeat home therapy. If the infant was less than 96 hours of age at initial treatment, then a longer duration of phototherapy was required. A potential bias was physician selection of families to participate with home phototherapy. The results may not be generalizable due to the equipment used and the large selection of phototherapy options available. In conclusion, this study adds to the growing body of literature demonstrating the efficacy of home phototherapy as an effective treatment for neonatal hyperbilirubinemia.

In 2020, Chu and colleagues published the results of a systematic review and meta-analysis to determine if home based phototherapy is as effective as hospital-based phototherapy. A total of 4 studies met inclusion criteria with 259 infants included, 138 infants received home phototherapy and 121 received hospital-based phototherapy. The rate of TSB decrease was not different in home-based phototherapy versus hospital-based phototherapy (standard mean deviation [SMD] = 32; 95% CI, -0.22-0.86; p=0.04). There was no significant difference in the duration of treatment between home-based phototherapy and hospital-based phototherapy (SMD = 0.59; 95% CI, 0.28-0.90; p=0.06). This meta-analysis further confirms the efficacy of home-based phototherapy as an effective alternative to hospital-based phototherapy for the reduction of TSB concentrations with comparable durations of therapy.

An unblinded randomized control trial (RCT) performed by Pettersson in 2021 set out to determine safety and efficacy, length of stay, and number of failed treatments in term newborns that were randomized to either home phototherapy or conventional in-hospital phototherapy. The study included 147 participants; of which, 78 were randomized to home phototherapy and 69 were randomized to conventional phototherapy. The secondary outcomes were weight gain during treatment and the number of blood samples taken. The inclusion criteria denoted that the newborns needed to have a gestational age above 36 + 0 weeks, a chronological age of more than 48 hours, and a TSB above 18 mg/dL between 48 and 72 hours of age or a TSB higher than 20.5 mg/dL after 72 hours of age. Additionally, the caregivers of the newborns needed to be capable of performing the therapy and agree to return to the hospital for daily checkups. The device used for home phototherapy was the BiliSoft^™ Phototherapy System (GE HealthCare, Chicago, IL) which is a single light-emitting diode fiber optic device. The control group receiving hospital-based phototherapy was treated with either the same BiliSoft unit and/or overhead devices. Caregivers in the study group were instructed to keep a diary of the duration of phototherapy, where the phototherapy took place, and the times the newborn was fed. The authors noted that no advice was given on nutrition or using formula, so the newborns were fed per the caregivers’ choice. The results showed that there were no statistically significant differences in the duration of treatment, weight change, amount of blood tests, or length of stay between the two groups. No participants required blood exchanges and 4% (n=3) of the participants in the study group were admitted to the hospital. All 3 participants received less than 10 hours of therapy under the lights within the previous 24 hours. There were three protocol violations in which infants received a treatment that they were not randomized to. These 3 participants were analyzed in the groups they were randomized to in accordance with the intention-to-treat principle. There were also 3 participants whose home therapy was discontinued due to the caregivers’ wishes. In the final analysis, 3 participants (2 in the control group and 1 in the study group) were not included because the families decided to stop taking part in the study. One participant in the control group was lost to follow-up. The authors concluded that for otherwise healthy newborns who have hyperbilirubinemia, home phototherapy could be a safe alternative to inpatient phototherapy if daily checkups and around-the-clock telephone support can be provided.

In 2023, Orringer and colleagues conducted a retrospective cohort study (through medical record review) of newborns (n=359) aged 2-8 days old with a diagnosis of hyperbilirubinemia (total serum bilirubin of 0.1 to 3.0 mg/dL below inpatient threshold) at their regularly scheduled outpatient newborn visit. The study purpose was to characterize home biliblanket treatment for hyperbilirubinemia. Investigators used Bilitool (an online resource based on the AAP hyperbilirubinemia guidelines) to assess neonatal hyperbilirubinemia risks and inpatient treatment thresholds. The study’s primary outcome was whether use of a biliblanket impacted hospital readmission. Of the 359 newborns, a total of 32 (9%) were readmitted for the treatment of hyperbilirubinemia. A total of 159 (44%) newborns used a home biliblanket. Just 6 (4%) newborns who used a biliblanket at home were readmitted compared to 26 (13%) of those who did not (p=0.002). The odds of being readmitted were significantly lower for newborns treated with a biliblanket (odds ratio [OR]=0.16; 95% CI, 0.06 to 0.44). The study authors concluded, “home biliblanket use was associated with lower odds of hospital readmission for newborn jaundice.” Study limitations included the lack of randomization, retrospective design, and limited sample size.

In 2024, Li and colleagues published results of a meta-analysis of RCTs and cohort studies to characterize the efficacy of home phototherapy compared to inpatient phototherapy for the treatment of hyperbilirubinemia in newborns. Outcome measures included duration of phototherapy, daily reduction of bilirubin levels, hospital readmission, and complications. A total of 9 studies comprised of 998 participants were included (4 RCTs and 5 cohort studies). Home phototherapy was associated with longer duration of therapy (p=0.03). Hospital readmission was significantly higher with home phototherapy (Risk Ratio [RR]=4.61; 95% CI, 1.43-14.86, p=0.01) whereas daily bilirubin reduction and complications were not significantly different. While the authors conclude, “…current evidence does not strongly support [home phototherapy] efficacy for neonatal hyperbilirubinemia, as high-quality data on long-term outcomes are scarce,” the limitations acknowledge the certainty of the evidence included in this review was “very low.” Furthermore, while readmissions were higher in the newborns receiving home phototherapy, readmissions did not appear to be driven by ineffectiveness of home phototherapy treatment as daily bilirubin reduction and complication rates were not significantly different. Further study is warranted.

Peer Reviewed Publications:

1. Chang PW, Waite WM. Evaluation of home phototherapy for neonatal hyperbilirubinemia. J Pediatr. 2020; 220:80-85.
2. Chu L, Qiao J, Xu C. Home-based phototherapy versus hospital-based phototherapy for treatment of neonatal hyperbilirubinemia: a systematic review and meta-analysis. Clin Pediatr (Phila). 2020; 59(6):588-595.
3. Li R, Li T, Yan X, et al. Efficacy of home phototherapy versus inpatient phototherapy for neonatal hyperbilirubinemia: a systematic review and meta-analysis. Ital J Pediatr. 2024; 50(1):37.
4. Moerschel SK, Cianciaruso LB, Tracy LR. A practical approach to neonatal jaundice. Am Fam Physician. 2008; 77(9):1255-1262.
5. Orringer K, Kileny S, Salada K, et al. Biliblanket utilization for outpatient treatment of newborn jaundice. Clin Pediatr (Phila). 2023; 62(7):725-732.
6. Pettersson M, Eriksson M, Albinsson E, Ohlin A. Home phototherapy for hyperbilirubinemia in term neonates-an unblinded multicentre randomized controlled trial. Eur J Pediatr. 2021; 180(5):1603-1610.
7. Tan KL. Comparison of the efficacy of fiberoptic and conventional phototherapy for neonatal hyperbilirubinemia. J Pediatr. 1994; 125(4):607-612.
8. Tan KL. Efficacy of bidirectional fiber-optic phototherapy for neonatal hyperbilirubinemia. Pediatrics. 1997; 99(5):E13.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for perinatal care. 8th ed. Elk Grove Village (IL): AAP; Washington, DC: American College of Obstetricians and Gynecologists; 2017.
2. Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022; 150(3):e2022058859.
3. Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2011;(12):CD007969.
4. Malwade US, Jardine LA. Home- versus hospital-based phototherapy for the treatment of non-haemolytic jaundice in infants at more than 37 weeks' gestation. Cochrane Database Syst Rev. 2014;(6):CD010212.
5. Okwundu CI, Okoromah CA, Shah PS. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database Syst Rev. 2012;(1):CD007966.

1. National Institutes of Health. Newborn jaundice. Reviewed January 24, 2023. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/001559.htm. Accessed on August 8, 2024.

BiliBed
BiliBlanket^®
Bili-lite^™
BiliSoft 2.0 Phototherapy System
BiliSoft Phototherapy System
Hyperbilirubinemia
Neonatal Jaundice
Phototherapy

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. 

Federal and State law, as well as contract language, and Coverage Guidelines take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association